You are here

Axovant

Sio Gene could be a canary in the coalmine for gene therapy

Sio Gene could be a canary in the coalmine for gene therapy

EP Vantage

Flag link:

In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate

In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate

Endpoints

Arvelle Therapeutics

Angelini Pharma

Flag link:

Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands

Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands

BioSpace

Sio Gene Therapies

Flag link:

Upcoming events – Avadel takes on Jazz and Axovant awaits early results

Upcoming events – Avadel takes on Jazz and Axovant awaits early results

EP Vantage

Jazz Pharmaceuticals

Parkinson's Disease

Flag link:

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival

Endpoints

Alzheimer's disease

Vivek Ramaswamy

urinary incontinence

Flag link:

Axovant trumpets new clinical data after gene therapy pivot

Axovant trumpets new clinical data after gene therapy pivot

Fierce Biotech

Parkinson's Disease

Flag link:

Axovant axes neuroscience drug, focuses on gene therapies

Axovant axes neuroscience drug, focuses on gene therapies

Pharmaforum

Flag link:

Axovant dumps nelotanserin in retreat from small molecule R&D

Axovant dumps nelotanserin in retreat from small molecule R&D

Fierce Biotech

dementia with Lewy bodies

clinical trials

small molecule drugs

Flag link:

Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

Endpoints

Flag link:

Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica

Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica

CP Wire

Oxford BioMedica

Flag link:

Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica

Oxford BioMedica

Flag link:

The stint that never happened? Biotech vet David Hung wipes Axovant from his work history

The stint that never happened? Biotech vet David Hung wipes Axovant from his work history

Stat

Flag link:

David Hung makes a quick, abrupt exit at Axovant after humiliating setbacks

David Hung makes a quick, abrupt exit at Axovant after humiliating setbacks

Endpoints

Flag link:

The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug

The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug

Stat

Alzheimer's disease

Flag link:

Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s

Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s

EP Vantage

Alzheimer's disease

Flag link:

The sector’s most valuable unpartnered assets – up for grabs or on the shelf?

The sector’s most valuable unpartnered assets – up for grabs or on the shelf?

EP Vantage

Portola Pharmaceuticals

DBV Technologies

Flag link:

3 Small Biotech Stocks Being Run by Proven Winners

3 Small Biotech Stocks Being Run by Proven Winners

Motley Fool

Esperion Therapeutics

Aurinia Pharmaceuticals

Richard Glickman

Flag link:

Key FDA Decision And Trial Dates In February

Key FDA Decision And Trial Dates In February

Seeking Alpha

Valeant Pharmaceuticals

Lexicon Pharmaceuticals

Amicus Therapeutics

Flag link:

Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies

Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies

TheStreet.com

Alzheimer's disease

Flag link:

Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug

Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug

Forbes

Alzheimer's disease

Flag link:

Pages